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Abstract Thyroid hormone exerts a large number of
inﬂuences on the cardiovascular system. Increased thyroid
hormone action increases the force and speed of systolic
contraction and the speed of diastolic relaxation and these
are largely beneﬁcial effects. Furthermore, thyroid hor-
mone has marked electrophysiological effects increasing
heart rate and the propensity for atrial ﬁbrillation and these
effects are largely mal-adaptive. In addition, thyroid hor-
mone markedly increases cardiac angiogenesis and
decreases vascular tone. These multiple thyroid hormone
effects are largely mediated by the action of nuclear based
thyroid hormone receptors (TR) the thyroid hormone
receptor alpha and beta. TRa is the predominant isoform in
the heart. Rapid nongenomic thyroid hormone effects also
occur, which can be clearly demonstrated in ex-vivo
experiments. Some of the most marked thyroid hormone
effects in cardiac myocytes involve inﬂuences on calcium
ﬂux, with thyroid hormone promoting expression of the
gene encoding the calcium pump of the sarcoplasmic
reticulum (SERCa2). In contrast, in hypothyroid animals
phospholamban levels, which inhibit the SERCa2 pump,
are increased. In addition, marked effects are exerted on the
calcium channel of the sarcoplasmic reticulum the ryano-
dine channel. Related to myoﬁbrillar proteins, myosin
heavy chain alpha is increased by T3 and MHC beta is
decreased. Complex and interesting interactions occur
between cardiac hypertrophy induced by excess thyroid
hormone action and cardiac hypertrophy occurring with
heart failure. The thyroid hormone mediated cardiac
hypertrophy in its initial phases presents a physiological
hypertrophy with increases in SERCa2 levels and
decreased expression of MHC beta. In contrast, pressure
overload induced heart failure leads to a ‘‘pathological’’
cardiac hypertrophy which is largely mediated by activa-
tion of the calcineurin system and the MAPkinases
signaling system. Recent evidence indicates that heart
failure can lead to a downregulation of the thyroid hormone
signaling system in the heart. In the failing heart, decreases
of thyroid hormone receptor levels occur. In addition,
serum levels of T4 and T3 are decreased with heart failure
in the frame of the non-thyroidal illness syndrome. The
decrease in T3 serves as an indicator for a bad prognosis in
the heart failure patient being linked to increased mortality.
In animal models, it can be shown that in pressure over-
load-induced cardiac hypertrophy a decrease of thyroid
hormone receptor levels occurs. Cardiac function can be
improved by increasing expression of thyroid hormone
receptors mediated by adeno-associated virus based gene
transfer. The failing heart may develop a ‘‘hypothyroid’’
status contributing to diminished cardiac contractile
function.
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Introduction
Thyroid hormone exerts a large number of inﬂuences on
the cardiovascular system involving cardiac contractile
effects, electrophysiological function, and cardiac structure
[1–3]. In addition, vascular tone, lipid levels and oxygen
consumption are markedly inﬂuenced by the thyroid status.
Related to cardiac contraction, thyroid hormone stimulates
the rate and force of systolic contraction and the rate of
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effects occur in animal models and patients with heart
failure. Electrophysiological effects manifest themselves as
an increased heart rate, which is sometimes apparent as
resting tachycardia in patients with hyperthyroidism. In
addition, an increased propensity to arrhythmias especially
atrial arrhythmias and atrial ﬁbrillation occurs [4, 5].
Increased thyroid hormone action of some duration mark-
edly stimulates the cardiac protein synthesis and leads to a
concentric cardiac hypertrophy [6, 7]. Return from a
hyperthyroid to a eu-thyroid status results in a return of the
cardiac hypertrophy to a normal cardiac conﬁguration. In
addition, less well recognized effects of thyroid hormones
are exerted on the cardiac vascular system with a promo-
tion of angiogenesis [8, 9]. Increased thyroid hormone
action leads to a decrease of the tone of arterial vascular
smooth muscle and a markedly decreased cardiac afterload
[10]. In contrast 20–40% of patients with hypothyroidism
can exhibit an increase in blood pressure [11]. Thyroid
hormone action also effects lipid level. Hypothyroidism
leads to increased cholesterol levels because of decreased
clearance and increased levels of LDL [12, 13]. Overall,
thyroid hormone stimulates metabolic rate and oxygen
consumption which results in a loss of body weight in the
majority of patients with hyperthyroidism.
Mechanisms of thyroid hormone action
in the cardiovascular system
Thyroid hormone acts in large part by binding to nuclear
thyroid hormone receptors [14]. Binding of the T3 ligand to
the thyroid hormone receptor results for a great majority of
genes in their increased transcription. In the absence of the
ligand T3, the thyroid hormone receptor can repress the
expression of genes leading to gene silencing. The com-
munication between the thyroid hormone and the basal
transcription machinery occurs through a complex set of
co-activators and co-repressors [15]. The ligand-activated
thyroid hormone receptor recruits co-activators which have
a positive stimulatory interaction with the basic transcrip-
tional machinery. In contrast recruitment of thyroid
hormone related co-repressors leads to decreased tran-
scription of thyroid hormone responsive genes. Thyroid
hormone responsive genes contain thyroid hormone
response elements (TRE’s) in their promoter, which can be
conﬁgured as cononical elements consisting of two direct
six nucleotide repeats spaced by a four nucleotide sequence
[14]. Other elements are composed as palindromic or
inverted palindromic TRE’s, and in addition, highly com-
plex TRE’s have been described [16]. Two genes, thyroid
hormone receptor alpha and thyroid hormone receptor beta,
encode thyroid hormone receptors. The thyroid hormone
receptor alpha gene encodes the ligand-activated thyroid
hormone receptor alpha 1 receptor. Due to alternate
splicing, thyroid hormone receptor alpha 2 does not bind to
thyroid hormone and has a weak silencing effect [14, 16].
In addition, short delta fragments of the thyroid hormone
receptor are expressed, which do no include the N and C
terminal portions of the T3 receptor protein [17]. This TR
delta alpha 1 and TR delta 2 fragments exert a dominant
negative effect. A speciﬁc splice variant of the thyroid
hormone receptor alpha, which is preferentially expressed
in mitochondria (P43, P28) has been described [18]. For
the thyroid receptor beta, the major transcript which is
ubiquitously present is the T3 binding thyroid hormone
receptor beta 1 isoform. The TR beta 2 isoform has a
different N-terminal conﬁguration and is preferentially
expressed in the central nervous system and the pituitary.
In addition, a TR beta 3 isoform is expressed in an ubiq-
uitous fashion at low levels and a delta isoform TR delta
beta 3 is expressed which exerts dominant negative effects
[16]. The mediation of nuclear T3 receptor-based thyroid
hormone action is therefore a complex process which is
inﬂuenced by the thyroid hormone concentration and the
level and type of the thyroid hormone receptors alpha and
beta isoforms. In addition the thyroid hormone receptors
can form homo and heterodimers, which is the most fre-
quently occurring form. The conﬁguration of the thyroid
hormone response elements onto which the TR binds, also
inﬂuences the thyroid hormone action. The important role
of interactions with co-repressors and co-activators was
already indicated and the interactions with cell-type spe-
ciﬁc factors can occur. These interactions lead to changes
in the histone acetylation status of chromatin.
In addition to the classical nuclear thyroid hormone
receptor-based mediation of T3 action recently rapid
effects of thyroid hormone especially in cell culture
experiments have been demonstrated [19]. The importance
of these effects under in vivo conditions is currently
explored actively. These rapid effects of thyroid hormone
may be mediated by the binding of thyroid hormone to
integrin-based receptors on the cell surface. It is also
possible that a subplasma membrane compartment of thy-
roid hormone receptors exist, as it has been described for
the estrogen receptor [20].
From gene to contractile effect
The diastolic function of the heart is inﬂuenced by the
thyroid status in a marked fashion. Hypothyroidism is
frequently combined with delayed diastolic relaxation of
the heart. The speed of diastolic relaxation of the heart is
markedly inﬂuenced by the lowering of the calcium levels.
In the mammalian cardiac myocyte, 70–90% of calcium
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123lowering is achieved by pumping of calcium into the sar-
coplasmic reticulum by the calcium ATPase of the
sarcoplasmic reticulum. This ATP consuming calcium
pump is inhibited by phospholamban. The phosphoalation
of phospholamban removes this inhibitory effect. In order
to demonstrate how thyroid hormone effects can alter the
expression of a speciﬁc gene leading to a contractile phe-
notype, the expression of the SERCa2 gene is considered.
Experiments in our laboratory using nuclear run-on assays
demonstrated that thyroid hormone stimulates the tran-
scription of the SERCa2 gene. We analyzed the promoter
of the SERCa2 gene in detail and found three different
thyroid hormone response elements. One of the elements is
a direct repeat and the second and the third element are
inverted palindromic elements. The thyroid hormone
response elements were mutated to non-functional TRE’s
which eliminated thyroid hormone effects on the activation
of the SERCa2 promoter [21, 22]. These mutational studies
also revealed that the ﬁrst TRE was the most powerful one
in mediating a stimulatory effect on the SERCa2 gene.
Thyroid hormone also effects the expression of phospho-
lamban. In the hypothyroid, heart phospholamban levels
are increased which will lead to an inhibition of SERCa2.
The mRNA level of the ryanodine channel is also markedly
increased with an increased thyroid status [2]. In addition
to inﬂuences on calcium handling, thyroid hormone inﬂu-
ences the expression of myoﬁbrillar proteins in important
ways. Thyroid hormone exerts a positive effect on the
transcription of the myosin heavy chain MHC alpha gene
inhibiting MHCb [2]. In contrast the mRNA and protein
levels of myosin heavy chain beta are decreased in hypo-
thyroid animals. Recent interesting studies have indicated
that MHC expression is modulated by micro RNA’s which
inﬂuence MHC mRNA turnover and translation [23].
Predominance of thyroid hormone receptor TR alpha
and beta in the heart and inﬂuences of thyroid
hormone receptor depletion
To explore in further detail the inﬂuence which the thyroid
hormone receptor isoforms TR alpha and TR beta have on
cardiac function, mice with an ubiquitous constitutional
knock out (KO) of TRa and TRb were used. The Tra KO
and TRbKO mice were generated by J. Samarut (Lyon,
France) [24] and provided on a collaborative basis. In
TRbKO mice, alpha Exon 5, 6, and 7 are deleted [24] and
for the thyroid hormone receptor beta Exon 4 and 5 are
removed [25]. TRaKO mice have low normal thyroid
hormone levels. In contrast, mice with deletion of TRb are
hyperthyroid most likely due to the loss of the inhibitory
effects of TRb on TSH expression. In order to achieve a
euthyroid status, the TRbKO mice are placed on a low
iodine/PTU diet and then replaced with a physiological
dose of thyroid hormone. Cardiac papillary function in
TRaKO and TRbKO knockout mice has been determined
[26, 27]. Cardiac capillary muscle function in TRaKO mice
were markedly abnormal showing delayed time for relax-
ation and decreased tension development [26]. In contrast,
the cardiac papillary muscle from TRbKO mice exhibited
normal contractile function. In addition, mice with the
deletion of TRa have a lower heart rate whereas TRbKO
mice exhibit a normal heart rate [26, 28]. The contractile
abnormalities observed in the hearts of TRaKO mice are in
line with the fact that thyroid hormone receptor alpha at the
mRNA and protein level presents 70% of all thyroid hor-
mone receptor present with thyroid hormone receptor beta
1 accounting for the remaining 20%. The marked effect of
thyroid hormone receptor alpha deletion on contractile
function could be explained by the fact that thyroid hor-
mone receptor alpha is the more predominant receptor or it
also could be due to speciﬁc qualitative characteristics of
the thyroid hormone receptor alpha which are different
from those of thyroid hormone receptor beta. Quantitative
versus qualitative effects of TR isoforms are further dis-
cussed below.
We also wanted to explore if the decrease in SERCa2
expression makes a signiﬁcant contribution to the delayed
diastolic contraction observed in hypothyroid mice.
Transgenic mice in which the SERCa2 transgene is driven
by a promoter not containing thyroid hormone response
elements were generated [27]. These transgenic mice and
wild type mice are made hypothyroid. Hypothyroid wild
type mice show delayed diastolic cardiac relaxation or
delayed relaxation of papillary muscle. In contrast,
SERCa2 transgenic mice made hypothyroid exhibit a nor-
mal contractile phenotype related to diastolic relaxation or
relaxation of papillary muscle. These ﬁndings therefore
indicate that the diastolic contractile effects mediated by
hypothyroidism are largely inﬂuenced by the calcium
handling of myocytes and decreased SERCa2 expression.
Holding SERCa2 levels in hypothyroid transgenic animals
at the normal levels leads to normal diastolic contractile
function.
Interaction between thyroid status cardiac
hypertrophy and heart failure
A longstanding debate has occurred in the literature if
cardiac hypertrophy can be separated into a physiological
versus a pathological type of cardiac hypertrophy [29, 30].
Physiological hypertrophy can be induced by exercise or
by increased thyroid hormone action. It is characterized by
increased SERCa2 levels, increased myosin heavy chain
(MHC) alpha levels, and decreased MHC beta levels. In
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ated by increase in pressure overload or hypertension with
the heart contracting against an increased after load. Some
of its hallmarks are decreases in SERCa2 levels, decreases
in MHCa levels, and increases in MHCa levels.
It has been proposed that different signaling members
mediate cardiac hypertrophy in physiological vs. patho-
logical hypertrophy. For physiological hypertrophy, one of
the models proposes that IGF1 binds to its receptor on
cardiac myocyte. This stimulates the activation of PI3
kinase leading to AKT phosphorylation which then initiates
changes in gene expression which are compatible with the
physiological cardiac hypertrophy phenotype. In contrast,
major players in pathological cardiac hypertrophy include
the activation of MAP kinase cascade with ERK1/2, p38
MAPK and JNK 1/2/3 [29]. In addition, the calcineurin
system plays an important role in pathological cardiac
hypertrophy [31]. A clear separation between physiological
and pathological hypertrophy is properly not feasible, and
over time, a compensated physiological hypertrophy may
result in cardiomyopathic dilatation and pathological type
of hypertrophy [30]. Interesting studies in which an AKT
transgene was expressed in a conditional manner in cardiac
myocytes showed that initially the hearts showed a pheno-
type which is compatible with physiological hypertrophy.
However, after 20 weeks duration, a phenotype, which is
more compatible with a dilated cardiomyopathy resulting in
decreased fractional shortening, occurred [32]. A contrib-
uting factor in the transition to a pathological hypertrophy
may have been inadequate vascular supply by capillary
density not keeping pace with the enlarging heart.
In summary, hyperthyroidism of limited duration can
lead to a compensated concentric cardiac hypertrophy.
Since hyperthyroidism is in general of a limited duration, a
physiological hypertrophic phenotype prevails. It also needs
to be noted that in hyperthyroid patients, tachycardia and
atrial ﬁbrillation can occur and some of the heart failure
observed in hyperthyroid patients may result from rate
related heart failure. Experiments using healthy dogs indi-
cate that pacing their hearts at an increasing rate results in
heart failure [33]. It also should be noted that patients with
hyperthyroidism who developed congestive heart failure
and a dilated cardiomyopathy have been reported [34, 35]
but this is an infrequent outcome. It is possible that these
patients did have underlying heart disease. It should also be
noted that in patients with hyperthyroidism, pulmonary
hypertension and right heart failure can occur [36, 37].
Hypothyroidism and heart failure
Several reports in the literature have indicated that hypo-
thyroidism can result in dilated cardiomyopathy and
congestive heart failure [38, 39]. In addition, subclinical
hypothyroidism can also increase the risk for heart failure
[40]. In one report, a cardiac biopsy was undertaken
because a cardiac transplant was planned before the
hypothyroidism was diagnosed [41]. The mRNA analysis
from the patient’s heart, when he was severely hypothyroid
indicated that MHCa was of markedly lower predominance
than after treatment for the hypothyroidism had occurred
with opposite changes for MHCb. In addition, ANF mRNA
was markedly elevated in the hypothyroid heart and not
detectable in the normal heart. Related to proteins involved
in calcium handling, phospholamban levels were 10-fold
higher in the hypothyroid than in the eu-thyroid heart [41].
Results in various animal models of hypothyroidism indi-
cate that the level and activity of SERCa2 is markedly
decreased and similar changes occur in animals or patients
with heart failure [42, 43]. These changes can be linked to a
decrease in diastolic relaxation. In addition, phospholam-
ban levels are markedly increased at the mRNA levels in
hypothyroid and failing hearts, further contributing to
decreased SERCa2 function and delayed diastolic relaxa-
tion [44, 45]. The ryanodine receptor is markedly
decreased in hypothyroid hearts [46] and due to alterations
in ryanodine receptor phosphorylation in failing hearts,
problems with appropriate calcium handling occur [47].
Ryanodine receptor abnormalities may be linked to
abnormal systolic function and a decrease in systolic force
generation [47]. Findings in transgenic mice expressing a
SERCa2 transgene driven by a promoter, which does not
contain thyroid hormone response elements, lead to a
complete rescue of the hypothyroid contractile phenotype
as mentioned above [27].
Interaction between T3 action and heart
failure-induced signaling mechanisms
A crosstalk between signaling cascades related to thyroid
hormone mediated increases in SERCa2 expression and
factors, which are altered in heart failure, have been noted
in the past. For example, when neonatal myocytes are
transfected with the SERCa2 promoter and b galactyocy-
dase (b-bal) reporter, addition of thyroid hormone leads to
a two-fold increase in expression of the 3.2 KB SERCa2
promoter driven b-bal reporter. Incubation of these neo-
natal myocytes with a combination of T3 and the cytokines
LIF and 1L-6 [48] completely abolished the T3 mediated
increase in SERCa2 promoter–reporter activity. These
ﬁndings indicate that increased levels of cytokines, as they
occur with heart failure, can markedly counteract thyroid
hormone-mediated increases in the expression of SERCa2.
It can be demonstrated that hypothyroidism, including
sub-clinical hypothyroidism, is a risk factor for heart
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result in delayed diastolic relaxation and abnormal calcium
handling. Both hypothyroidism and heart failure lead to
decreased expression of SERCa2. In addition, the inhibi-
tory action of phospholamban is enhanced, either due to
increased phospholamban expression or due to decreased
phospholamban phosphorylation. Heart failure is fre-
quently accompanied by elevated cytokine levels and
cytokines oppose the positive regulatory effects of thyroid
hormone on SERCa2 expression.
Heart failure and ischemia decrease thyroid
hormone signaling members
Interactions between thyroid hormone action and heart
failure are also noted in the non-thyroidal illness syndrome
(NTIS). The non-thyroidal illness syndrome results, when
severe systemic illness including heart failure or myocar-
dial infarction leads to changes in the function of the
hypothalamic pituitary axis. A decrease in T4 to T3 con-
version occurs, which is followed by decreased secretion of
thyroid stimulating hormone (TSH) and diminished thyroid
hormone release from the thyroid gland. Hallmark labo-
ratory ﬁndings of NTIS are decreases in T3, increases in
reverse T3, which are followed by decreases in T4 and
TSH. With recovery from the severe illness, a rebound
happens and TSH levels can exceed the upper normal range
for a short while before re-adjustment to a normal condi-
tion occurs and normalization of thyroid hormone levels
follows. It is interesting to note that cytokines have been
invoked to play a signiﬁcant role in inducing the non-
thyroidal illness syndrome. Several recent reports indicate
that a very strong correlation exists between the decrease in
T3 levels induced by congestive heart failure and the sur-
vival [49]. The report demonstrates that the lower the heart
failure-induced decrease in T3 is the more signiﬁcant of a
decrease in survival occurs. The connection between thy-
roid hormone signaling and heart failure is also
documented in studies in which thyroid hormone receptor
levels were determined in explanted hearts from patients
undergoing cardiac transplantation [50]. In one report, a
signiﬁcant decrease of thyroid hormone receptor alpha 1
expression and an increase in the non-ligand binding thy-
roid hormone receptor alpha 2 isoform were noted [50]. We
pursued these studies in a mouse model using ascending
aortic constriction to induce cardiac hypertrophy and heart
failure [51]. We then quantitated the mRNA level for
thyroid hormone receptor alpha 1 and beta 1. Both thyroid
hormone receptor alpha 1 and beta 1 were signiﬁcantly
decreased in the pressure overloaded failing hearts. Other
investigators have reported that ischemic heart disease
leads to alterations in thyroid hormone receptor levels [52].
In addition, it has been reported that in ischemic heart
disease the deiodinase type 3, which converts T4 to the
biologically inactive reverse T3 is markedly elevated [53].
Furthermore, inducing right cardiac ventricular hypertro-
phy by a model of pulmonary hypertension resulted in
signiﬁcant increases in the type 3 diodonase (D3) [54]. The
mechanism leading to D3 induction was explored in more
detail and the HIF1 alpha factor was found to directly
stimulate the promoter of the T3 deiodinase gene resulting
in increased T3 expression [55].
It could therefore be postulated that a close interaction
between thyroid hormone action and normal cardiac
function occurs. Hypothyroidism, including sub-clinical
hypothyroidism, presents a risk to develop heart failure. In
addition, the non-thyroidal illness syndrome, which is in
part, mediated by cytokines leads to decreased thyroid
hormone receptor levels in the failing heart and in some
speciﬁc conditions to increased conversion of T4 to the
biologically inactive reverse T3. It could therefore be
postulated that the non-thyroidal illness syndrome gener-
ates a ‘‘hypothyroid’’ heart characterized by decreased T3
levels and decreased thyroid hormone receptor levels. It is
therefore an interesting question to examine if increasing
thyroid hormone action in the failing heart will result in
improved cardiac function.
In order to address the question if increasing T3 action in
the failing heart improves cardiac function, we pursued
the following studies. Ascending aortic constriction was
induced in mice, which resulted in pressure overload-
induced heart failure [51]. As it was mentioned above, thy-
roid hormone receptoralpha and beta levels are decreasedin
these hearts. In order to restore thyroid hormone receptor
levels toward the normal range, thyroid hormone receptor
alpha1andbeta1wereclonedintoadeno-associatedviruses
and injected into the left ventricular wall of the heart. In
addition, some of these animals received a physiological
replacement dose of 3.5 ngT3/gBW per day. Two weeks
after administration of viral vector-based thyroid hormone
receptor expression and T3 administration, the rate of car-
diac relaxation was determined. When we determined dP/dt
min as a parameter of cardiac relaxation, we noted that in
pressure overloaded heart with increased expression of thy-
roid hormone receptor alpha or thyroid hormone receptor
beta, a very signiﬁcant increase in the speed of diastolic
relaxation occurred, however complete normalization was
not achieved. The addition of a T3 replacement dose did not
lead to a further signiﬁcant increase in contractile improve-
ment. It has also been reported that a tetracycline system-
based inducible increased the expression of the deiodinase
type 2, which converts T4 to T3, in the heart of animals with
pressure overload-induced cardiac hypertrophy led to a
signiﬁcant improvement in systolic and diastolic contractile
function [56].
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increasing thyroid hormone levels in failing hearts by AV
expression leads to a signiﬁcant and equal rescue effect by
thyroid hormone receptor alpha 1 and beta 1. In addition,
increasing T3 levels in the failing heart by increasing D2
activity also markedly improves contractile function. It
appears therefore that the heart failure-induced lowering of
thyroid hormone levels or thyroid hormone receptor levels
in the failing heart exerts a mal-adaptive effect.
Previous studies in human beings, in which T3 therapy
was administered to patients after cardiac surgery revealed
a beneﬁcial effect in lowering the incidence of atrial
ﬁbrillation [57]. In other studies thyroxin treatment had a
beneﬁcial effect on dilated cardiomyopathy [58]. A very
recent trial indicates that T3 replacement in patients with
heart failure has beneﬁcial contractile effects [59]. It
should also be noted that in other studies intravenous T3
administration to patients undergoing coronary artery
bypass graft surgery in randomized double-blind placebo
controlled trials did not lead to signiﬁcant cardiac
improvement [60]. Overall, it appears that in failing hearts,
a hypothyroid cardiac state may occur due to decreased
thyroid hormone and thyroid hormone receptor levels in
failing hearts. Animal studies and a limited number of
human trials indicate that increasing thyroid hormone
action either by increasing T3 receptor levels or T3 in itself
can improve cardiac function without signiﬁcant detri-
mental effects. It is currently unclear if long term
administration of thyroid hormone to patients in heart
failure will be well tolerated and will lead to increased
survival. Excessive thyroid hormone administration lead-
ing to a hyperthyroid state needs to be avoided because
negative electrophysiological consequences such as an
increase in heart rate and cardiac arrhythmias could result.
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